Qiagen has entered a commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for ...

Investing.com -- Qiagen NV (NYSE:QGEN) reported fourth-quarter adjusted per share profit of 62 cents and sales of $540 million, thanks to growth in tuberculosis testing and diagnostics. Shares were ...

Qiagen’s next-generation sequencing tests are already used to look for genetic variants that may shed light on an individual’s specific case of cancer and potential treatment options, but the ...

Qiagen N.V. (NYSE:QGEN) ranks among the oversold European stocks to buy. On March 13, Deutsche Bank upgraded Qiagen N.V.

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...

Qiagen (NYSE:QGEN) said it completed the acquisition of DNA-biometrics company Verogen for $150M. Verogen develops DNA-based biometric human identification products for analysis of forensic genomic ...

ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through ...

Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 VENLO, Netherlands-- ...

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system ...

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free ...